| 000 | 01930cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030304.0 | ||
| 008 | 101007s2010 ua d f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.11.01.Ph.D.2010.He.E | ||
| 100 | 0 | _aHeba Omar Ahmed Omar | |
| 245 | 1 | 0 |
_aEffect of recombinant activated factor VII (rFVIIa) on intraoperative blood loss during pediatric brain surgery : _bA clinical and thromboelastographic study / _cHeba Omar Ahmed Omar ; Supervised Iman Riad M. Abdelaal , Enas M. Ghareeb Elshazly , Mohamed Ibrahem Sonbati |
| 246 | 1 | 5 | _aتأثير العامل السابع معاد الإتحاد النشط على فقدان الدم أثناء العملية في جراحة المخ للأطفال |
| 260 |
_aCairo : _bHeba Omar Ahmed Omar , _c2010 |
||
| 300 |
_a158 P. : _bcharts ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Anaesthesia | ||
| 520 | _aThere is a clinical need for one or more new hemostatic agents to supplement a help in controlling bleeding in pediatric brain tumor, which cannot be controlled by surgical intervention, local hemostatic agents and transfusion of blood products. Recombinant activated factor VII has been approved by the U.S Food and Drug Administration (FDA) for nearly a decade for the prevention and treatment of bleeding episodes in hemophilic patients with inhibitors to coagulation factor VIII or factor IX | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aCoagulopathy | |
| 653 | 4 | _aHemostasis | |
| 653 | 4 | _aRFVIIa | |
| 700 | 0 |
_aEnas Ghareeb Elshazly , _eSupervisor |
|
| 700 | 0 |
_aIman Riad Abdelaal , _eSupervisor |
|
| 700 | 0 |
_aMohamed Ibrahem Sonbati , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c31623 _d31623 |
||